ICON (NASDAQ:ICLR) Posts Earnings Results, Beats Estimates By $0.08 EPS

ICON (NASDAQ:ICLR - Get Free Report) released its quarterly earnings data on Wednesday. The medical research company reported $3.26 earnings per share for the quarter, topping analysts' consensus estimates of $3.18 by $0.08, Briefing.com reports. ICON had a net margin of 9.82% and a return on equity of 10.95%. The company had revenue of $2.02 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same period in the prior year, the firm earned $3.75 earnings per share. The firm's revenue for the quarter was down 4.8% compared to the same quarter last year. ICON updated its FY 2025 guidance to 13.000-14.000 EPS.

ICON Stock Performance

Shares of NASDAQ ICLR traded down $8.00 during midday trading on Friday, reaching $187.01. 1,598,447 shares of the stock were exchanged, compared to its average volume of 1,571,695. The firm has a market cap of $15.10 billion, a price-to-earnings ratio of 19.24, a PEG ratio of 2.82 and a beta of 1.17. ICON has a twelve month low of $125.10 and a twelve month high of $338.67. The firm has a 50-day simple moving average of $144.57 and a two-hundred day simple moving average of $163.41. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35.

Analysts Set New Price Targets

Several research firms have commented on ICLR. Robert W. Baird raised shares of ICON from a "neutral" rating to an "outperform" rating and increased their price target for the company from $150.00 to $224.00 in a research report on Thursday. The Goldman Sachs Group decreased their price target on shares of ICON from $180.00 to $160.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. TD Cowen downgraded shares of ICON from a "buy" rating to a "hold" rating and cut their price objective for the company from $254.00 to $157.00 in a report on Monday, April 14th. Mizuho upped their price objective on shares of ICON from $173.00 to $225.00 and gave the company an "outperform" rating in a report on Friday. Finally, Citigroup cut their price objective on shares of ICON from $290.00 to $215.00 and set a "buy" rating on the stock in a report on Monday, April 7th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $219.54.

ICON Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.